Best Genomics Companies in Boston, United States
The 68 best Genomics companies in Boston, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Ginkgo Bioworks.
Ranked: Best Genomics companies in Boston
| # | Company | Disclosed funding | Last round | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|
| 1 | Ginkgo Bioworks 🦄 Autonomous labs for biotechnology, empowering scientists to design the living world | $796M | 30 mo ago | 1,218 | Austin Che Co-Founder | 385 patents Engineering microbes for biosynthesis of drugs, flavors, proteins, and immune therapeutics | — |
| 2 | Genuity Science Provider of omics data analysis solutions for researchers | $515M | 90 mo ago | 140 | Jeff Gulcher Co-Founder & CSO | — | — |
| 3 | Asimov Provider of integrated suite for advanced genetic design and manufacturing | $209M | 41 mo ago | 64 64 → 119 (+86%) · sector median +47% | Chris Voigt Co-Founder | 70 patents Efficient manufacturing of recombinant viral vectors for gene therapy applications | 1 launch · 1 partnership |
| 4 | Ensoma Developer of in vivo hematopoietic stem cell engineering for genomic medicine | $205M | 37 mo ago | 52 52 → 51 (-2%) · sector median +47% | — | 62 patents Adenoviral gene‑therapy vectors enabling multi‑lineage therapeutic expression and stem‑cell mobilization | — |
| 5 | Proteostasis Developer of novel therapeutics for neurological disease | $168M | 102 mo ago | 11 | — | — | — |
| 6 | Akouos Developer of gene therapies to restore and preserve hearing capabilities in genetically defined populations | $163M | 75 mo ago | 92 | Manny Simons Founder & CEO | 279 patents Gene‑therapy and inner‑ear drug delivery for non‑age‑related sensorineural hearing loss. | — |
| 7 | Variantyx Provider of genomics data analysis platform for healthcare | $125M | 25 mo ago | 122 122 → 226 (+85%) · sector median +47% | Haim Neerman Co-Founder & CEO | — | 3 job openings · 1 launch |
| 8 | Exosome Diagnostics Developer of blood-based cancer molecular diagnostics for patient stratification and disease monitoring | $119M | 107 mo ago | 51 | — | 230 patents Exosome-based biomarker detection for cancer, autoimmune diseases, and liquid biopsy diagnostics | — |
| 9 | Ascidian Therapeutics Developer of RNA therapeutics to treat genetic diseases | $90M | 31 mo ago | 37 37 → 48 (+30%) · sector median +47% | Michael Ehlers Founder & CEO | — | 1 job opening · 4 partnerships |
| 10 | Stylus Medicine Developer of gene-based therapeutics for multiple diseases | $85M | 13 mo ago | 21 | — | — | — |
| 11 | WAVE Life Sciences RNA medicines to transform human health, treating rare and common disorders | $84M | 130 mo ago | 233 233 → 381 (+64%) · sector median +47% | Paul Bolno President and CEO | 128 patents Therapeutic oligonucleotides for RNA interference, exon skipping, and gene modulation. | 1 launch · 1 partnership |
| 12 | INTERGALACTIC THERAPEUTICS Developer of gene therapies for the treatment of multiple diseases | $75M | 56 mo ago | 34 | — | — | — |
| 13 | DeepCure AI-driven drug discovery platform for inflammation & immunology space | $72M | 26 mo ago | 22 22 → 27 (+23%) · sector median +47% | Kfir Schreiber Co-Founder & CEO | 10 patents AI-driven drug discovery and automated chemical synthesis workflow optimization | — |
| 14 | Precede Developer of liquid biopsy platform providing disease-defining biology from blood tests | $57M | 32 mo ago | — | Rehan Verjee Co-Founder & CEO | — | 1 award |
| 15 | Day Zero Diagnostics Developer of genome sequencing-based diagnostics for infectious diseases | $49M | 33 mo ago | 52 | Jong Lee CEO & Cofounder | — | — |
| 16 | Good Start Genetics Genetic testing company improving health and lives through accessible genetic information | $32M | 157 mo ago | 128 | — | 154 patents Patents concentrated in chemistry & materials | — |
| 17 | New Equilibrium Biosciences AI-based computational-experimental platform for drug discovery | $20M | 50 mo ago | 10 | Virginia Burger Founder & CEO | — | — |
| 18 | Aldatu Biosciences Innovative PCR diagnostics for infectious diseases, advancing global health emergency response | $18M | 45 mo ago | 11 | — | — | — |
| 19 | 4D Path Developer of precision medicines for the treatment of cancer 35Talent top 28%Patents top 31%Funding top 37%Moat top 38% All 8 signals ▾Talenttop 28% Patentstop 31% Fundingtop 37% Moattop 38% Innovationtop 41% Techbottom 38% Globalbottom 37% Marketbottom 23% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Patents: 46 patents matched (strict assignee match) · 15 filings since 2022 vs 13 in 2017-21 rank vs industry peers · Fliar Intelligence Index 35/100 | $17M | 1 mo ago | 10 | Rodrigo Navarro Co-Founder & CEO & President | 45 patents Nanostructured drug delivery systems and malaria transmission-blocking vaccine technologies. | — |
| 20 | Genialis Developer of end-to-end bioinformatics software solutions | $15M | 6 mo ago | 35 | Rafael Rosengarten Chief Executive Officer | 17 patents Integrating and bias‑correcting multi‑omics data for predictive cancer therapy modeling | 1 launch |
| 21 | Thrive Bioscience Developer of smart devices for life science cell culture | $15M | 105 mo ago | 35 | Thomas Farb Co-Founder & COO | 162 patents Automated imaging, analysis, and IoT-controlled systems for cell culture monitoring and management | — |
| 22 | Transcode Therapeutics Developer of mRNA therapeutics to treat cancer | $13M | 18 mo ago | 19 19 → 16 (-16%) · sector median +47% | — | — | — |
| 23 | CureLab Developer of immunostimulants and vaccines against cancer | $7M | 220 mo ago | 10 | — | 8 patents Designing engineered nucleic acid sequences for vaccine and therapeutic applications | — |
| 24 | Flexomics Provider of screening platform for functional and genomic analysis | $6M | 28 mo ago | 4 | Magali Soumillon Co-Founder | 2 patents Optical barcode-based biosensing platforms for molecular interaction analysis | 1 launch |
| 25 | Tiba Biotech Provider of fully synthetic RNA vaccine drug delivery technology | $6M | 9 mo ago | 16 | Christian W Mandl Co-Founder | 58 patents Patents concentrated in health & consumer products | — |
| 26 | Novophage Developer of a synthetic biology platform for pathogen detection in food | $6M | 180 mo ago | — | Micah Rosenbloom CEO | — | — |
| 27 | Inform Genomics Provider of pharmacogenomics tools for cancer | $6M | 125 mo ago | 1 | — | — | — |
| 28 | Genospace Bridging clinical research and care with data-driven precision medicine | $5M | 141 mo ago | 22 22 → 42 (+91%) · sector median +47% | — | — | — |
| 29 | Frameshift Cloud-based genomic data analytics & visualization platform for researchers | $5M | 33 mo ago | 12 | Chase Miller Co-Founder & CTO | — | — |
| 30 | Parsagen Diagnostics Christian non-profit providing therapeutic riding with volunteer support | $4M | 125 mo ago | — | Ruben Salinas CEO & President | — | — |
| 31 | InnoTech Precision Medicine Developer of multimodal molecular diagnostic platform for early disease detection | $3M | 10 mo ago | 5 | Reza Mollaaghababa Co-Founder | — | 1 internship · 1 launch |
| 32 | Curoverse Biomedical data solutions empowering precision medicine through open source technology | $2M | 135 mo ago | 15 | — | — | — |
| 33 | EnEvolv Engineers microorganisms to produce chemicals, enzymes and small molecules for variety of industries. | $2M | 114 mo ago | 607 | — | 30 patents Molecular and cell‑free biosensor platforms for detecting specific analytes and engineering genomes | — |
| 34 | Molecular Loop Developer of technology for targeted DNA sequencing | $2M | 52 mo ago | 12 | Greg Porreca Founder and CEO | 17 patents Genomic sequencing and structural variant detection using multiplex nucleic acid methods | — |
| 35 | Klogenix Developer of therapeutics for the treatment of age-related diseases | $1M | 84 mo ago | — | Carmela Abraham Founder | 10 patents Biotech tools for gene expression modulation and DNA‑binding protein therapeutics | — |
| 36 | Predictus Biosciences Developer of in-vitro diagnostic test for cancer | $500K | 185 mo ago | — | Ajit Bharti Founder & CEO | — | — |
| 37 | Cellaria Biosciences Provides Xenografts, screening services etc for cancer drug discovery. | $150K | 73 mo ago | 11 | — | — | — |
Top 12 Genomics companies in Boston
#1
Series B · Boston, Massachusetts · founded 2016 · 10 employees$17.1Mraised▾
4D Path is a developer of precision medicines for the treatment of cancer. It has developed medicines for cancer diagnosis and it provides therapeutic molecular overexpression profiles. It has developed precision diagnostics solutions that help in identify cancer types, subtypes, variants & mimics, surgical margin, and others.
- May 2026Series B—
- May 2023Series B$13M
- Jul 2020Series A$4.1M
#2
Series A · Boston, Massachusetts · founded 2015 · 35 employees$15.3Mraised▾
Developer of end-to-end bioinformatics software solutions. It combines biomedical data management, customizable data analysis pipelines, and interactive visualizations. Its platform is a complete data ecosystem, a solution for sequencing data management, analysis, visualization, and dissemination. It claims that this platform can be easily configured locally or on the cloud and also offers web-based software that automates data management and analysis tasks.
- Dec 2025Series A$700K
- Jan 2023Series A$13M
- Oct 2021Grant (prize money)—
- Nov 2017Seed$2.3M
#3
Series A · Boston, Massachusetts · founded 2022 · 21 employees$85Mraised▾
Developer of gene-based therapeutics for multiple diseases. It offers genome engineering and chromatin regulation technology for developing delivery methods for enzymes and drugs to provide targeted gene editing in-vivo.
- May 2025Series A$85M
#4
Public · Boston, Massachusetts · founded 2008 · 1218 employees$795.8Mraised▾
Autonomous labs for biotechnology, empowering scientists to design the living world. They provide autonomous labs and cloud lab services, enabling scientists to automate experimental work and focus on insight and creativity. The company offers solutions and datapoints services to design experiments and address research goals. Their autonomous systems lift the burden of manual lab work, empowering scientists to ask critical questions. They provide hardware, software, support, and cloud lab resources. The company's vision is to enable programming biology, curing diseases, and growing everything imaginable. This is a B2B tech company offering SaaS solutions for biotechnology and pharmaceutical industries.
- Dec 2023Grant (prize money)—
- Aug 2023Grant (prize money)$387.5K
- Jun 2023Grant (prize money)$650K
- May 2020Series E$70M
#5
Funding Raised · Boston, Massachusetts · founded 2017 · 16 employees$6Mraised▾
Provider of fully synthetic RNA vaccine drug delivery technology. It has developed proprietary molecular systems for nucleic acid delivery and offers fully synthetic thermostable RNA vaccine technology, that delivers the nucleic acid into the patient’s cells upon vaccination. It encodes one or more proteins, to assemble antigens and drive immunity against various diseases.
- Aug 2025Grant (prize money)$2.9M
- Apr 2025Grant (prize money)$300K
- Jun 2022Grant (prize money)$300K
- Feb 2022Grant (prize money)$2.2M
#6
Funding Raised · Boston, Massachusetts · founded 2021 · 5 employees$2.9Mraised▾
Developer of multimodal molecular diagnostic platform for early disease detection. It focuses on creating diagnostic solutions, particularly for cancer, by integrating molecular biology and engineering. The company's platform aims to provide accurate and accessible diagnostics to empower patients and healthcare providers. It develops and commercializes a diagnostic platform that utilizes multimodal detection to identify disease biomarkers. The company collaborates with scientists, engineers, and clinicians to ensure its diagnostic platform meets patient care standards.
- Aug 2025Grant (prize money)$329.7K
- Apr 2025Grant (prize money)$756K
- Jan 2025Grant (prize money)$756K
- Sep 2023Grant (prize money)$329.7K
#7
Series C · Boston, Massachusetts · founded 2014 · 122 employees$125Mraised▾
Provider of genomics data analysis platform for healthcare. The company has developed an integrated platform for the analysis, interpretation, and reporting of NGS data for diagnosis. The diagnostic platform uses whole-genome sequencing (WGS) data generated through collaboration with sequencing partners, automated data analysis with clinical report generation, and interpretation to provide a comprehensive molecular diagnostic service for a wide range of disease areas.
- Apr 2024Series C$36M
- Oct 2023Series C—
- Oct 2022Conventional Debt$21M
- Feb 2022Series C$41.5M
#8
Public · Boston, Massachusetts · founded 2015 · 19 employees$13.3Mraised▾
Developer of mRNA therapeutics to treat cancer. The company's product line include TTX-MC138 focused on treating metastatic cancer. Other drug candidates include TTX-siPDL1, TTX-siLIN28b, TTX-RIGA, TTX-CRISPR, and TTX-mRNA, focusing on treating cancer using RNA technology.
- Nov 2024Post IPO$8M
- Sep 2024Grant (prize money)$2M
- Sep 2024Grant (prize money)$1M
- Aug 2021Grant (prize money)—
#9
Series A · Boston, Massachusetts · founded 2018 · 22 employees$72Mraised▾
Developer of a drug discovery platform designed to improve the breadth and accuracy of pre-clinical drug development. The company's platform combines deep learning algorithms, cloud computing infrastructure and a proprietary database of chemistries to find drug candidates that deliver improved value to patients, enabling healthcare organizations to get drugs rapidly and at an affordable price.
#10
Series B · Boston, Massachusetts · founded 2019 · 52 employees$205Mraised▾
Developer of in vivo hematopoietic stem cell engineering for genomic medicine. The company’s technology platform enables in vivo engineering of hematopoietic stem cells. It combines an off-the-shelf in vivo delivery system with a gene engineering toolkit. The vision is for a hematopoietic stem cell engineering platform that selectively and durably modifies cells of the hematopoietic system with the intent to treat diseases with versatility. The aim is to shape a new patient experience defined by simplicity, speed and safety.
- May 2023Series B$50M
- Jan 2023Series B$85M
- Feb 2021Series A$70M
#11
Series B · Boston, Massachusetts · founded 2017 · 64 employees$209.4Mraised▾
Provider of integrated suite for advanced genetic design and manufacturing. The platform offers cloud-based software and advanced genetic design tools to optimize the development and manufacture of biologics, cell therapies, and gene therapies.
- Jan 2023Series B$175M
- 2020Series A$25M
- May 2019Series A$6.9M
- Mar 2018Series A$3.7M
#12
Series A · Boston, Massachusetts · founded 2020 · 37 employees$90Mraised▾
Developer of RNA therapeutics to treat genetic diseases. The company's platform offers technology to replace mutated exons that cause disease and perform large-scale DNA and RNA synthesis, for the treatment of various diseases.
- Nov 2023Series A$40M
- Oct 2022Series A$50M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Boston researches in bioinformatics
- Boston Children\'s Hospital12
- Boston University9
- Boston Engineering3
- Boston Medical Center3
- Boston College2
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.